MET and neoplasm: There may, however, be another explanation for the relatively low levels of METΔ7–8 in clinical tumors: in the patient tumor from which the E98 model was generated, a low percentage of MET-expressing tumor cells was detected, although it is impossible to determine whether these cells carry the METΔ7–8 mutation because the antibodies used do not discriminate between MET and METΔ7–8.